Catalpol suppresses proliferation and facilitates apoptosis of MCF-7 breast cancer cells through upregulating microRNA-146a and downregulating matrix metalloproteinase-16 expression

Chuan Liu, Fan Wu, Yuanwei Liu, Cong MengMolecular 2015 · DOI

Abstract

Breast cancer remains a significant global health challenge, with Matrix metalloproteinase-16 (MMP-16) playing a critical role in tumor invasion. This study investigates the anti-tumor potential of catalpol, a primary active ingredient of Rehmannia. Using MCF-7 breast cancer cells, we evaluated the effects of catalpol on cell proliferation, apoptosis, and the expression of MMP-16 and microRNA-146a (miR-146a). Our results indicate that catalpol significantly inhibits proliferation and promotes apoptosis in a dose-dependent manner. Mechanistically, catalpol upregulates miR-146a, which subsequently downregulates MMP-16 expression. These findings suggest that the miR-146a/MMP-16 axis is a key pathway through which catalpol exerts its therapeutic effects in breast cancer.

Introduction

Breast cancer is the most prevalent malignancy in women and a leading cause of cancer-related mortality. Invasive progression is often facilitated by the degradation of the extracellular matrix, a process mediated by Matrix Metalloproteinases (MMPs). Specifically, MMP-16 has been identified as a potent enhancer of breast cancer cell invasion. Concurrently, microRNAs like miR-146a have emerged as vital regulators of gene expression in cancer pathology. Catalpol, an iridoid glucoside found in Rehmannia, has demonstrated various pharmacological benefits, including anti-tumor properties. This study aims to elucidate whether catalpol can modulate the miR-146a/MMP-16 axis to suppress breast cancer progression.

Methods

The human breast cancer cell line MCF-7 was treated with varying concentrations of catalpol (0, 25, 50, and 100 µg/ml). Cell viability was assessed using the MTT assay (measuring absorbance at 570 nm) over 72 hours. Apoptosis was quantified through Caspase-3 activity assays and flow cytometry. To investigate the molecular mechanism, RT-qPCR was used to measure miR-146a levels, and gelatin zymography/Western blotting assessed MMP-16 activity and expression. Gain-of-function and loss-of-function experiments using miR-146a mimics and inhibitors were conducted to confirm the regulatory relationship between miR-146a and MMP-16.

Results

Inhibition of Proliferation and Induction of Apoptosis

Catalpol treatment resulted in a significant, dose-dependent reduction in MCF-7 cell viability. As shown in the MTT assay results, higher concentrations and longer exposure times led to a marked decrease in A570 nm values. Simultaneously, catalpol induced programmed cell death, evidenced by a significant increase in Caspase-3 activity, particularly at the 50 and 100 µg/ml doses.

Figure 3: Catalpol inhibits MCF-7 cell proliferation (A) and increases Caspase-3 activity (B) in a dose-dependent manner.

Downregulation of MMP-16

A critical finding of this study was the impact of catalpol on the invasive marker MMP-16. Protein expression levels of MMP-16 were significantly reduced following treatment with catalpol. This suppression was most evident at the highest concentration (100 µg/ml), suggesting that catalpol directly interferes with the molecular machinery responsible for tumor invasiveness.

Figure 4: Catalpol treatment leads to a dose-dependent decrease in MMP-16 protein expression levels.

The miR-146a/MMP-16 Regulatory Axis

Molecular analysis revealed that catalpol treatment significantly upregulated the expression of miR-146a. Transfection experiments further demonstrated that overexpressing miR-146a could mimic the effects of catalpol by reducing MMP-16 levels. Conversely, inhibiting miR-146a blocked the ability of catalpol to suppress MMP-16, confirming that miR-146a acts as a necessary intermediary in this therapeutic pathway.

Discussion and Conclusion

This study provides compelling evidence that catalpol acts as a potent anti-proliferative and pro-apoptotic agent in MCF-7 breast cancer cells. By triggering the upregulation of miR-146a, catalpol effectively "silences" the expression of MMP-16, thereby inhibiting the invasive potential of the cells.

While these results are promising, they are currently limited to in vitro observations in a single cell line (MCF-7). Future research should focus on validating these mechanisms in animal models and exploring the efficacy of catalpol against more aggressive, hormone-receptor-negative breast cancer subtypes. In conclusion, catalpol represents a promising natural lead compound for the development of novel breast cancer therapies targeting the miR-146a/MMP-16 axis.

Summary updated

Abstract

Breast cancer is the most common malignancy in women, and was the second highest cause of mortality in women in 2013. Matrix metalloproteinase-16 (MMP-16) is an enhancer of the invasion of breast cancer cells. The expression of microRNA‑146a (miR‑146a) has been reported to be significantly greater in patients with breast cancer compared with healthy controls. Catalpol is one of the main active ingredients of Rehmannia, of which the key pharmacological effects are antitumoral and antiproliferative. The present study was performed to investigate the effect of catalpol on breast cancer and to explore the potential therapeutic mechanisms. Cell proliferation was investigated using an MTT assay, and caspase‑3 activity assays and flow cytometry were used to assess apoptosis in MCF‑7 breast cancer cells. The expression levels of MMP‑16 and miR‑146a were investigated using gelatin zymography assays and reverse transcription-quantitative polymerase chain reaction, respectively. In addition, MCF‑7 cells were transfected with miR‑146a and anti‑miR‑146a to further investigate the effects of catalpol. The results demonstrated that catalpol reduced proliferation and promoted apoptosis in MCF‑7 cells, reducing MMP‑16 activity and increasing the expression of miR‑146a in MCF‑7 cells. This suggests that miR‑146a may regulate and control the expression levels of MMP‑16 in MCF‑7 cells. In conclusion, catalpol suppresses proliferation and facilitates apoptosis of MCF‑7 breast cancer cells through upregulating miR‑146a and downregulating MMP-16 expression.
BibTeX
@inproceedings{liu2015catalpol,
  author = {Chuan Liu and Fan Wu and Yuanwei Liu and Cong Meng},
  title = {{Catalpol suppresses proliferation and facilitates apoptosis of MCF-7 breast cancer cells through upregulating microRNA-146a and downregulating matrix metalloproteinase-16 expression}},
  booktitle = {Molecular},
  year = {2015},
  doi = {10.3892/mmr.2015.4361},
}
Figure